Nancy C. Ondovik

Sr. Director, NewCo Development

  • Focus: All sectors (Pharmaceutical, medical device, consumer and digital health)
  • Based in New Brunswick, New Jersey
  • Fun Fact: Based Enjoys kayaking, stand-up paddle boarding & beach days

Nancy serves as Sr. Director, NewCo Development and is responsible for supporting the creation and launch of newly defined companies aligned with the strategic needs of Johnson & Johnson’s business sectors.

Most recently, Nancy served as Senior Director, Transactions in support of the Cardiovascular, Metabolism & Retina Therapeutic Area and was responsible for leading the evaluation, negotiation, and execution of numerous business development transactions including the license agreement with MeiraGTx for its inherited retinal disease portfolio and the collaboration with Bristol-Myers Squibb on milvexian. In addition to these deals essential to CVM’s current pipeline, Nancy has led the negotiation of several research collaborations, royalty monetization deals, internal asset spinouts, option agreements, and regional co-promotion deals.

Nancy has also been responsible for the successful management of several key strategic global alliances.

Prior to her transaction role in CVM, Nancy was Director, Corporate Development and was responsible for acquisition deals supporting the pharmaceutical group. Nancy worked closely with the oncology team to identify and assess multiple company acquisition opportunities and in 2009, led the team responsible for the acquisition of Cougar Biotechnology.

Nancy holds a Bachelor of Science in Pharmacy and a Doctor of Pharmacy degree, from Rutgers, The State University of New Jersey. In addition, Nancy holds an MBA, with a concentration in Finance, from Rutgers Business School.

Nancy C. Ondovik
Nancy C. Ondovik